title: Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.
abstract: The use of recombinant adeno-associated viruses (rAAVs) ushered in a new millennium of gene transfer for therapeutic treatment of a number of conditions, including congenital blindness, hemophilia, and spinal muscular atrophy. rAAV vectors have remarkable staying power from a therapeutic standpoint, withstanding several ebbs and flows. As new technologies such as clustered regularly interspaced short palindromic repeat genome editing emerge, it is now the delivery tool-the AAV vector-that is the stalwart. The long-standing safety of this vector in a multitude of clinical settings makes rAAV a selling point in the advancement of approaches for gene replacement, gene knockdown, gene editing, and genome modification/engineering. The research community is building on these advances to develop more tailored delivery approaches and to tweak the genome in new and unique ways. Intertwining these approaches with newly engineered rAAV vectors is greatly expanding the available tools to manipulate gene expression with a therapeutic intent.
authors.affiliation: Departments of Pediatrics and Genetics, Stanford University , Stanford, California.
authors.forename: Paul N
authors.initials: PN
authors.lastname: Valdmanis
authors.affiliation: Departments of Pediatrics and Genetics, Stanford University , Stanford, California.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Kay
mesh_terms: D000229:Dependovirus / Q000235:genetics*; D000072669:Gene Editing / Q000379:methods; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics* / Q000627:therapeutic use; D006801:Humans; D034622:RNA Interference
keywords: AAV vectors; RNAi; genome editing; miRNA; non-coding RNA